Locations
St. John's, NL, Canada
industry
Health · Medical Devices
Size
11-50 employees
Stage
Seed
founded in
2016
Optimal Congestive Heart Failure (CHF) management requires detection of increasing cardiac filling pressures. Current alternatives require a surgical implantable device and are expensive. JVPLabs enables physicians to monitor increasing cardiac pressures using a non-invasive medical device that accurately measures the Jugular Venous Pressure (JVP). We have automated the current standard of care by simplifying the complex, time-consuming, and inaccurate task of JVP assessment. Monitoring the JVP height is the cornerstone for in-hospital management of CHF as it enables medication adjustment, discharge planning, and nutritional recommendations. JVP assessment requires a physician at the bedside and, unfortunately, is not available in the home – the very place it is most needed to keep patients feeling well and out of the hospital. The JVPHome (research use only) is a comprehensive remote patient monitoring device that provides automated and non-invasive monitoring of right-sided cardiac pressures via measurement of the Jugular Venous Pressure (JVP). Additional vital signs easily captured by the patient with the press of a single button include heart rate, respiratory rate, SpO2, ECG, and blood pressure. Clinical care teams now have critical pressure measurements enabling them to adjust and optimize care for Congestive Heart Failure (CHF) patients to keep them feeling well and out of the hospital. JVPLabs enables hospital quality monitoring across the continuum of care and, most importantly, provides critical data enabling care teams to effectively manage CHF patients in their home. Reason to believe: • Automating the current standard of care with 80% improvement over current practice • Excellent usability data with proven ease of use in an elderly patient population • Strong leadership team with proven track record and multiple successful exits • Cardiologists in the US, Canada, and UK love our approach and are seeking to include our device in trials
Something looks off?